Ceskova 1993.

Methods	Allocation: randomised (no further description). Blindness: double (administered as monotherapy in oral solution). Duration: 8 weeks. Consent: not stated. Setting: hospital.
Participants	Diagnosis: schizophrenia & schizoaffective disorder (ICD‐9). N=62. Sex: 45M, 17F. Age: mean ˜ 36 years. History: hospitalised, chronic with mean duration of illness ˜ 10 years. Exclusions: not stated.
Interventions	1. Risperidone: 2‐20mg/day. N=31. 2. Haloperidol: 2‐20mg/day. N=31. Antiparkinsonian medication, minor tranquillizers or promethazine, dihydroergotamine as required.
Outcomes	Adverse effects: various observed effects. Leaving the study early. Discharge from hospital. Unable to use ‐ Global effect: Serejskij's modified scale (no SD). Mental state: BPRS (no SD). Side effects: DVP (no SD), use of antiparkison medication (individual group data not given).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear